Valensa International obtains two US patents for joint health formulations

49e20df1-1551-4aa3-8258-f95e0101fefearticleimage.jpg

04 Oct 2017 --- The US Patent and Trademark Office has awarded Florida-based Valensa International two new patents, locking down patent protection for the core ingredients related to the company’s FlexPro MD and FlexPro ES. In clinical trials, these dietary formulations for joint health were shown to be three to five times more effective in relieving joint discomfort than a standard commercial formulation of glucosamine and chondroitin. 

The first of the two patents was granted for Flexuron Plus, Valensa’s proprietary, non-animal derived and highly-bioactive formula that features Medium-Chain Hyaluronic Acid (which has a lower molecular weight than traditional hyaluronic acid), when used in combination with the antioxidant Astaxanthin. Flexuron Plus is now available for licensing as a separate ingredient or finished product. 

The second patent was granted to Valensa for their bioavailable Zanthin Astaxanthin that has been coupled with Phospholipids. The Flexuron Plus blend of Zanthin Astaxanthin (a down-regulator of pro-inflammatory cytokines) and immunogenic hyaluronic acid, enhanced in the presence of phospholipid-based surfactants, has been clinically shown to dramatically reduce knee joint discomfort. In recent clinical trials, Valensa has demonstrated that this multi-patented blend works fast and has a cumulative beneficial effect over time on maximizing joint comfort.

Valensa’s joint formulations, including FlexPro MD and FlexPro ES, are available for multiple distribution channels, including retail mass market and specialty health stores.

According to Umasudhan C.P., CEO of Valensa, the ever-growing patent family protecting Flexuron Plus allows Valensa to develop the next generation of highly potent and mechanism-based joint formulations.

The human clinical study measuring the effectiveness of FlexPro MD, which contains Flexuron Plus, showed dramatic and nearly linear continuous improvement in joint discomfort over the 56-day clinical trial period. This trial showed that FlexPro MD was three to five times more effective in relieving joint discomfort than a standard commercial formulation of glucosamine and chondroitin (positive control arm) or the placebo control arm. Furthermore, joint discomfort began as early as seven days from trial initiation and by the end of the study subjects reported that they were essentially “pain-free.”

“Animal studies as well as in vitro cell culture work using real-time Polymerase Chain Reaction, or PCR, confirmed that our mechanism-based approach to product design was not only extremely effective and commercially rewarding, but also provided us with an extended vision into the design of even more potent and cost-effective next-generation joint healthcare products,” says Dr. John Minatelli, Sr. VP Business Development at Valensa who led the product development and clinical trials for FlexPro MD and Flexuron Plus.

In related news, Valensa International recently partnered up with Kemin Industries to jointly supply and market BetaVia ingredients, immune-supporting beta-glucans sourced from a proprietary strain of algae (Euglena gracilis), in the US dietary supplement and functional food and beverage markets. 

This partnership creates a two-armed sales approach to the US dietary supplement and functional foods and beverages markets. The Kemin sales team will service the functional food and beverage customers, while Valensa’s sales team will service customers producing dietary supplements.

“Valensa and its affiliate Parry Nutraceuticals are market leaders in microalgae-based supplements with well-established ingredient brands in over 30 countries,” Umasudhan C.P. says about the partnership. “The relationship with Kemin allows us to introduce novel immunity supplement formulations made stronger by BetaVia, to our omnichannel customer base in the US and internationally.”

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Food Ingredients News

DMK’s “sweeping transformation” in full swing as turnover rises to €5.8bn

22 Jun 2018 --- German dairy cooperative and company, the DMK Group has gone through some significant changes that have given rise to a €5.8 billion turnover, paying above-average milk prices to dairy farmers and becoming Europe’s largest supplier of milk produced without genetic modification.

Nutrition & Health News

Weekly Digest: Probiotics reduce bone loss in older women, Optibiotix expands reach in Italy

22 Jun 2018 --- This week in nutrition, Australian Whole Grain Week launched a new diet database in the hope to enhance healthy diets across the country. In research news, UK scientists warn that the normalization of plus-size body shapes may undermine obesity reduction efforts, while probiotics were found to have a significant protective effect for the bones of older women, and further research found that four cups of coffee seemed to protect the heart. Optimum Nutrition and Faber embarked on a campaign to improve American travel snacking habits and Optibiotix and Alfasigma partnered to commercialize Optibiotix's probiotic supplement in Italy. Lastly, this year’s Institute of Food Technologist (IFT18) in Chicago, US, will see NZMP launching a new milk protein ingredient and Lycored delivering some excitement on the floor with “culinary art.”

Nutrition & Health News

DuPont microbiome venture inks third partnership on probiotics

21 Jun 2018 --- A new collaboration with Institut National de la Recherche Agronomique (INRA) Micalis-MGP will concentrate on DuPont’s probiotic strains and the understanding of these microbes’ mechanism of action on human health. The move is hoped to continue DuPonts Microbiome Venture capacity building – through strategic partnerships – in microbiome innovation.

Packaging & Technology News

Raised Real: Maximizing nutrition and minimizing waste in infant nutrition

19 Jun 2018 --- Tapping into a space opened up by “millennial parents” who want nutritious food for their infants, with an environmentally-friendly seal of appeal, is Raised Real. The California start-up offers an innovative baby food meal-kit delivery solution, touting nutritionally balanced meals and an innovative freeze-cooling packaging system. Speaking to Santiago Merea, CEO and co-founder, Steven Kontz, co-founder and CFO and Benish Shah, VP of Marketing, NutritionInsight looks into how the company is minimizing food waste while maximizing nutrition and protecting the environment through packaging choices. 

Nutrition & Health News

Infant nutrition (part 1): Challenges in feeding the first 1,000 days

18 Jun 2018 --- The World Health Organization (WHO) solidly recommends breastfeeding for infants. However, there are situations – medical, situational or personal – that necessitate good quality breast milk substitutes (BMS), such as formulas. In a bid to produce a formula that is closest in composition to human breast milk, manufacturers face a range of unique R&D challenges. In this two-part series on Infant Nutrition, NutritionInsight speaks to a number of key suppliers and experts about these challenges.

More Articles
URL : http://www.nutritioninsight.com:80/news/valensa-international-obtains-two-us-patents-for-joint-health-formulations.html